Quince Therapeutics Names Brigette Roberts CEO Amid Restructuring
QNCX has more than doubled off its 52-week low of $15.1.
Summary
Quince Therapeutics appointed Brigette Roberts as CEO effective October 8, 2026. The move follows the October 6 stockholder approval of the Series C Preferred conversion and the October 9 8-K disclosing a rebrand to IRulya Therapeutics with a new CEO, CFO, COO, and four new directors. Roberts' appointment is part of a broader leadership overhaul as the company navigates going concern doubts and a Nasdaq delisting notice. The company reported a $75.5M Q2 loss and negative stockholders' equity of $35.3M. The new CEO's background and strategic direction are not yet disclosed. The company has changed its name to Irulya Therapeutics.
At the time of this announcement, QNCX was trading at $31.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.9M. The 52-week trading range was $15.10 to $909.98. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.